Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives Approval for Additional Phase II Trial of RECCE® 327 Topical Gel for Diabetic Foot Infections

Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing open-label study protocolProgram...
April 10, 2025 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

A$5.0 million commitment received from Australian-based private investorA$10.8 million Entitlement Offer at the same offer price as the placementFunds to support Phase III Topical clinical trials in...
February 27, 2025 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-Infectives

SYDNEY, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (Recce or the Company) the Company developing a new class of synthetic anti-infectives, today announced it...
February 19, 2025 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Reports Positive Data from Phase II Trial of RECCE® 327 Gel in Acute Bacterial Skin and Skin Structure Infections, Supporting Accelerated Commercialization Pathway

Phase II trial assessed the efficacy and safety of RECCE® 327 topical gel in patients with acute bacterial skin and skin structure infections (ABSSSI), including those with diabetic foot infections...
January 22, 2025 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Preliminary data indicates patients experienced either a complete cure or significant improvement in infection symptoms following treatment with R327GFull data analysis expected in Q1 2025Additional...
December 10, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives Approval from Indonesia’s Drug and Food Authority for Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Registrational Phase 3 trial for diabetic foot infections to be conducted across Indonesia, one of the world's largest diabetes patient populationsAwarded expedited regulatory review status in...
November 27, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives

SYDNEY, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, today announced the Australian Patent Office...
November 12, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives Ethics Approval in Indonesia to Commence Registrational Phase 3 Trial of RECCE® 327 Topical Gel in Diabetic Foot Infections

Human Research Ethics Committee approval received for registrational Phase 3 trial for RECCE® 327 topical gel in patients with diabetic foot infectionsRegistrational Phase 3 clinical trial for...
November 06, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Advances Patient Dosing to Final Stages in Phase II Trial for Acute Bacterial Skin and Skin Structure Infections

Trial reaches dosing milestone, with 20 of the 30 total patients dosedAll patients dosed met the primary endpoints of the study, either a cure or notable improvement following treatment with RECCE®...
October 31, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Interim Efficacy Data and Safety Approval for Phase II ABSSSI Clinical Trial

RECCE® 327 Topical Gel (R327G) was demonstrated to be safe and well-tolerated in patients – R327G demonstrating highly encouraging efficacy results as determined by non-Data Safety Monitoring BoardAll...